WW Med+ Program Expands GLP-1 Access to Medicare Members Through Bridge Program
WW has more than doubled off its 52-week low of $8.365 on light trading volume (0.4× avg).
Summary
Weight Watchers Med+ program now offers Medicare beneficiaries access to GLP-1 medications through the Medicare GLP-1 Bridge Program. Eligible members can purchase GLP-1s for $50 per month from July 2026 through December 2027, with WW assisting with insurance navigation. This specific expansion to the Medicare demographic, following the general Med+ GLP-1 announcement on June 4th, is crucial for subscriber growth given the company's recent Q1 revenue decline and subscriber losses. The subsidized pricing makes GLP-1s more accessible, potentially driving significant adoption for WW's key strategic pivot.
At the time of this announcement, WW was trading at $17.00 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $164M. The 52-week trading range was $8.37 to $46.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.